Efficacy and adverse effects of venlafaxine in children and adolescents with ADHD: A systematic review of non-controlled and controlled trials

Reviews on Recent Clinical Trials

Volumn 8, Issue 1, 2013, Pages 2-8

  Ghanizadeh, Ahmad ^a,b   Freeman, Roger D ^c   Berk, Michael ^d,e,f,g  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d DEAKIN UNIVERSITY   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

ADHD; Noradrenaline; Treatment; Trial; Venlafaxine

Indexed keywords

METHYLPHENIDATE; VENLAFAXINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; PEDIATRICS; PRIORITY JOURNAL; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XEROSTOMIA;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS AS TOPIC; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHYLPHENIDATE; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS;

EID: 84874891059     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887111308010002     Document Type: Article

References (44)

1. Faraone, S.V., et al., Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry, 2008. 47(9): p. 994-1009.
2. Brookshire, B.R. and S.R. Jones, Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. Synapse, 2012. 66(9): p. 844-847.
3. Masand, P.S. and S. Gupta, The safety of SSRIs in generalised anxiety disorder: any reason to be anxious? Expert Opin Drug Saf, 2003. 2(5): p. 485-93.
4. Amiri, S., et al., Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol, 2012. 27(1): p. 76-81.
5. Emslie, G.J., et al., Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. J Am Acad Child Adolesc Psychiatry, 2007. 46(4): p. 479-88.
6. Gibbons, R.D., et al., Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebocontrolled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry, 2012.
7. Leeder, J.S., Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am, 2001. 48(3): p. 765-81.
8. Leeder, J.S., Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today, 2004. 9(13): p. 567-73.
9. Ereshefsky, L. and D. Dugan, Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depress Anxiety, 2000. 12 Suppl 1: p. 30-44.
10. Sabljic, V., K. Ruzic, and R. Rakun, Venlafaxine withdrawal syndrome. Psychiatr Danub, 2011. 23(1): p. 117-9.
11. Dalley, J.W. and J.P. Roiser, Dopamine, serotonin and impulsivity. Neuroscience, 2012. 26: p. 42-58.
12. Liberati, A., et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 2009. 6(7): p. e1000100.
13. Elia, N. and M.R. Tramer, Ketamine and postoperative pain--a quantitative systematic review of randomised trials. Pain, 2005. 113(1-2): p. 61-70.
14. Lynch, M.E. and F. Campbell, Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol, 2011. 72(5): p. 735-44.
15. Volkers, A.C., E.R. Heerdink, and L. van Dijk, Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf, 2007. 16(9): p. 1054-62.
16. Bond, G.R., A.C. Garro, and D.L. Gilbert, Dyskinesias associated with atomoxetine in combination with other psychoactive drugs. Clin Toxicol (Phila), 2007. 45(2): p. 182-5.
17. Pary, R., et al., Attention deficit disorder in adults. Ann Clin Psychiatry, 2002. 14(2): p. 105-11.
18. Hollander, E., et al., Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol, 2000. 15(2): p. 132-5.
19. Krause, K.H., J. Krause, and G.E. Trott, [Hyperkinetic syndrome (attention deficit-/hyperactivity disorder) in adulthood]. Nervenarzt, 1998. 69(7): p. 543-56.
20. Hornig, M., Addressing comorbidity in adults with attentiondeficit/hyperactivity disorder. J Clin Psychiatry, 1998. 59 Suppl 7: p. 69-75.
21. Popper, C.W., Antidepressants in the treatment of attentiondeficit/hyperactivity disorder. J Clin Psychiatry, 1997. 58 Suppl 14: p. 14-29; discussion 30-1.
22. Pleak, R.R. and L.J. Gormly, Effects of venlafaxine treatment for ADHD in a child. Am J Psychiatry, 1995. 152(7): p. 1099.
23. Bond, D.J., et al., The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attentiondeficit/hyperactivity disorder. Ann Clin Psychiatry, 2012. 24(1): p. 23-37.
24. Vitiello, B., Recent NIMH clinical trials and implications for practice. J Am Acad Child Adolesc Psychiatry, 2008. 47(12): p. 1369-74.
25. Pityaratstian, N., Advances in alternative pharmacotherapy of ADHD. J Med Assoc Thai, 2005. 88 Suppl 4: p. S357-62.
26. Maidment, I.D., The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol, 2003. 17(3): p. 332-6.
27. Popper, C.W., Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am, 2000. 9(3): p. 605-46, viii.
28. Findling, R.L. and J.W. Dogin, Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry, 1998. 59 Suppl 7: p. 42-9.
29. Findling, R.L., et al., Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 2007. 17(4): p. 433-45.
30. Mukaddes, N.M. and O. Abali, Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. Psychiatry Clin Neurosci, 2004. 58(1): p. 92-5.
31. Olvera, R.L., et al., An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol, 1996. 6(4): p. 241-50.
32. Zarinara, A.R., et al., Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol, 2010. 25(7-8): p. 530-5.
33. Firoozkoohi, M., et al., [Efficacy of venlafaxine and methylphenidate in the treatment of children with attention deficit hyperactivity disorder]. TABIB-E-SHARGH, 2008. 10(2): p. 69-77.
34. Ghanizadeh, A., M.R. Mohammadi, and R. Moini, Comorbidity of psychiatric disorders and parental psychiatric disorders in a sample of Iranian children with ADHD. J Atten Disord, 2008. 12(2): p. 149-55.
35. Hosenbocus, S. and R. Chahal, SSRIs and SNRIs: A review of the discontinuation syndrome in children and adolescents. J Can Acad Child Adolesc Psychiatry, 2011. 20(1): p. 60-7.
36. Jacob, M.K. and P. Ash, Venlafaxine-induced complex visual hallucinations in a 17-year-old boy. J Clin Psychiatry, 2009. 70(4): p. 601-3.
37. Tripp, A.C. and S.A. Golden, Transient complex visual hallucinations with venlafaxine treatment: a case report. Prim Care Companion J Clin Psychiatry, 2009. 11(2): p. 83.
38. Koga, M., et al., Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. Acta Psychiatr Scand, 2009. 120(4): p. 329-31.
39. Iraqi, A.H., A case report of paranoid delusion with venlafaxine use. J Am Geriatr Soc, 2003. 51(7): p. 1045-6.
40. Fava, M., et al., Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry, 1997. 154(12): p. 1760-2.
41. Ghanizadeh, A. and S. Mosallaei, Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome. Brain Dev, 2009. 31(1): p. 15-9.
42. Palumbo, D., et al., Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol, 2004. 14(2): p. 185-94.
43. Ronsley, R., et al., Do Hospital and Community SSRI Usage Patterns in Children and Adolescents Match the Evidence? J Can Acad Child Adolesc Psychiatry, 2010. 19(3): p. 218-26.
44. Faraone, S.V. and T.E. Wilens, Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. J Clin Psychiatry, 2007. 68 Suppl 11: p. 15-22.